同仁堂科技(01666.HK)漲逾9%創逾一年高 與母企等組合營從事醫藥電商業務
同仁堂科技(01666.HK)與母企等成立合營從事醫藥電商業務,該股今早升破去年7月所創52周高位6.96元,最高見7.48元,創15個月高,現造7.22元,升9.4%,成交急增至661萬股,涉資4,771萬元。
同仁堂科技公布,昨天與母企同仁堂股份(持有公司46.85%股權)、同仁堂商業及白兔信息訂立成立合營公司合同,從事醫藥電商業務。合營註冊資本5,000萬元人民幣(下同),公司、同仁堂股份、同仁堂商業及白兔信息分別佔合營25%、25%、26%及24%權益,將分別出資1,250萬元、1,250萬元、1,300萬元及1,200萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.